

# EL.EN.

**OUTPERFORM** 

Sector: Industrials Price: Eu12.88 - Target: 15.70

# **Continuation of Strong Demand Trends Fuels Better Guidance**


Andrea Randone +39-02-77115.364 andrea.randone@intermonte.it Francois Robillard: +39-02-77115.470 francois.robillard@intermonte.it

Stock Rating			
Rating:		Ur	changed
Target Price (Eu):		from 17.10	to 15.70
	2022E	2023E	2024E
Chg in Adj EPS	2.0%	0.4%	0.4%

### **Next Event**

3Q22 Results Out November 14th 2022

### El.En. - 12M Performance



Stock Data			
Reuters code:			ELEN.MI
Bloomberg code:			ELN IM
Performance	1M	3M	12M
Absolute	-8.5%	12.6%	-13.8%
Relative	-5.1%	11.3%	1.0%
12M (H/L)		17.	90/11.24
3M Average Volui	me (th):		63.59

Shareholder Data	
No. of Ord shares (mn):	78
Total no. of shares (mn):	78
Mkt Cap Ord (Eu mn):	1,010
Total Mkt Cap (Eu mn):	1,010
Mkt Float - Ord (Eu mn):	535
Mkt Float (in %):	53.0%
Main Shareholder:	
Cangioli Andrea	14.8%

Balance Sheet Data	
Book Value (Eu mn):	303
BVPS (Eu):	3.86
P/BV:	3.3
Net Financial Position (Eu mn):	95
Enterprise Value (Eu mn):	981

- Continued strong sales growth and solid margins in 2Q, as expected: sales rose +16% YoY to €183mn (our estimate €182mn/+15%). Medical segment sales grew +21% to €96mn (vs. our €96mn/+20%), primarily driven by strong Surgical sales (+47%) and another great performance outside Europe (ROW +26%), but ongoing weakness in Japan. Industrial sales also grew +11%, with Italy & EU (+48%) offsetting Covid-hit China (ROW -8%). EBITDA was in line with our forecast at €27mn (+15%), a 14.9% margin (flat) as cost inflation and the normalisation of marketing activities drove fixed costs up, offsetting the better sales mix; higher growth in Medical activities drove a +0.9pp YoY gross margin gain. 2Q EBIT (€24mn/+1.9pp margin YoY) and 1H net income (€28mn/+9% YoY) were also in line with our forecast.
- Efforts to ensure steady component supply magnify seasonal 2Q cash burn: NFP shrank markedly in 2Q to a still-positive €44mn (vs. €86/116mn in 1Q22/FY21). ELN invested heavily in WC in 2Q (€-32mn total) to ensure continuity of production by stockpiling components (raw mat. inventories up €15mn) and ensuring priority in sourcing (€14mn impact in 1H of higher advances paid to suppliers and lower advances from clients, mainly in China). Tax (€7mn impact on WC in 1H), dividends (€17mn) and higher CapEx (€5mn net in 2Q) added to the cash burn, outweighing robust earnings. NFP does not include €21mn of liquid financial assets. WC should partly normalise as a % of sales in 2H (vs. the high 1H level), supporting 2H FCF.
- Sales guidance lifted amid as demand remains strong: ELN lifted its FY22 sales guidance, pointing to "over €660mn" i.e. >+15.5% growth (a c.+6% upgrade vs. previous guidance for "above +10%"). This was motivated by still-high backlogs (notwithstanding rising production) and a reiterated positive outlook on demand strength despite the macroeconomic environment and supply chain difficulties. The broad EBIT guidance was confirmed (up YoY), with the 2H22 margin seen just below 1H (12.7%). This reflects a continuation of Medical trends and still-lower activity in China, hindering ELN's ability to fully tap into potential operating leverage. Any sign of a return to normal business conditions in China would increase the chances of a further guidance upgrade.
- Change in estimates: we are slightly lifting our FY22 sales forecast to €665mn in light of the strengthened positive outlook, while fine-tuning our EBIT margin to 12.1% (implying a 2H22 EBIT margin of 11.5% vs. 12.7% in 1H22, 11.4% in 2H21). We are lowering our NFP forecast to €95mn (from €124mn) reflecting higher CapEx and a partial recovery of the 1H cash burn in 2H22, amid some WC normalisation.
- OUTPERFORM; TP €15.7 (from €17.1) on higher risk-free rate: we remain positive as we appreciate the ongoing robust growth and re-affirmed positive outlook. The market has penalised the high 2Q cash burn (the stock fell -7.7% yesterday), ignoring i) the raised guidance, set to contribute further to earnings momentum as reflected in our new estimates, and ii) the expected (at least partial) WC reversal in 2H22. We are lowering our DCF-based TP to reflect a higher risk-free rate (+0.5pp). The stock trades at 18.0x/16.6x P/E '22/'23, a c.20% discount to 3Y average multiples following a c.40% de-rating since November 2021.

Key Figures & Ratios	2020A	2021A	2022E	2023E	2024E
Sales (Eu mn)	408	571	665	720	775
EBITDA Adj (Eu mn)	43	80	94	101	108
Net Profit Adj (Eu mn)	19	45	56	61	65
EPS New Adj (Eu)	0.244	0.580	0.715	0.775	0.834
EPS Old Adj (Eu)	0.244	0.580	0.701	0.772	0.831
DPS (Eu)	0.100	0.200	0.200	0.200	0.200
EV/EBITDA Adj	10.5	10.6	10.4	9.1	8.2
EV/EBIT Adj	13.9	13.1	12.2	10.6	9.4
P/E Adj	52.7	22.2	18.0	16.6	15.4
Div. Yield	0.8%	1.6%	1.6%	1.6%	1.6%
Net Debt/EBITDA Adj	-1.6	-1.4	-1.0	-1.5	-1.7

The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein, and any of its parts, is strictly prohibited. None of the contents of this document may be shared with third parties without Company authorization. Please see important disclaimer on the last page of this report



### DISCLAIMER (for more details go to DISCLAIMER)

IMPORTANT DISCLOSURES
The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein and of any its parts is strictly prohibited. None of the contents of this document may be shared with third parties without authorisation from Intermonte.

This report is directed exclusively at market professional and other institutional investors (Institutions) and is not for distribution to person other than "Institution" ("Non-Institution"), who should not rely on this material. Moreover, any

The information and data in this report have been obtained from sources which we believe to be reliable, although the accuracy of these cannot be guaranteed by Intermonte. In the event that there be any doubt as to their reliability, this will be clearly indicated. The main purpose of the report is to offer up-to-date and accurate information in accordance with regulations in force covering "recommendations" and is not intended nor should it be construed as a solicitation to buy or sell securities.

This disclaimer is constantly updated on Intermonte's website www.intermonte.it under LEGAL INFORMATION. Valuations and recommendations can be found in the text of the most recent research and/or reports on the companies in question. For a list of all recommendations made by Intermonte on any financial instrument or issuer in the last twelve months consult the PERFORMANCE web page.

Intermente distributes research and engages in other approved activities with respect to Major U.S. Institutional Investors ("Majors") and other Qualified Institutional Buyers ("QIBs"), in the United States, via Brasil Plural Securities LLC under SEC 15a-6 guidelines. Intermonte is not registered as a broker dealer in the United States under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and is not a member of the Securities Investor Protection Corporation ("SIPC"). Brasil Plural Securities LLC is registered as a broker-dealer under the Exchange Act and is a member of SIPC.

ANALYST CERTIFICATION For each company mention ANALYSI CERTIFICATION

For each company mentioned in this report the respective research analyst hereby certifies that all of the views expressed in this research report accurately reflect the analyst's personal views about any or all of the subject issuer (s) or securities. The analyst (s) also certify that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation or view in this report.

The analyst (s) responsible for preparing this research report receive(s) compensation that is based upon various factors, including Intermonte's total profits, a portion of which is generated by Intermonte's corporate finance activities, although this is minimal in comparison to that generated by prokerage activities.

Intermonte's internal procedures and codes of conduct are aimed to ensure the impartiality of its financial analysts. The exchange of information between the Corporate Finance sector and the Research Department is prohibited, as is the

exchange of information between the latter and the proprietary equity desk in order to prevent conflicts of interest when recommendations are made.

The analyst responsible for the report is not an expectable special properties of the U.S. through Brasil Plural Securities LLC, 545 Madison Avenue, New York 1002.

### **GUIDE TO FUNDAMENTAL RESEARCH**

The main methods used to evaluate financial instruments and set a target price for 12 months after the investment recommendation are as follows:

- Discounted cash flow (DCF) model or similar methods such as a dividend discount model (DDM)
- Comparison with market peers, using the most appropriate methods for the individual company analysed: among the main ratios used for industrial sectors are price/earnings (P/E), EV/EBITDA, EV/EBIT, price /sales. Return on capital and multiples of adjusted net book value are the main methods used for banking sector stocks, while for insurance sector stocks return on allocated capital and multiples on net book value and e value are used

  For the utilities sector comparisons are made between expected returns and the return on the regulatory asset base (RAB)

  The section of the distriction of the return o

Some of the parameters used in evaluations, such as the risk-free rate and risk premium, are the same for all companies covered, and are updated to reflect market conditions. Currently a risk-free rate of 2.5% and a risk premium of 5.0% are being used.
Frequency of research: quarterly.

Reports on all companies listed on the S&PMIB40 Index, most of those on the MIDEX Index and the main small caps (regular coverage) are published at least once per quarter to comment on results and important newsflow. A draft copy of each report may be sent to the subject company for its information (without target price and/or recommendations), but unless expressly stated in the text of the report, no changes are made before it is published

Explanation of our ratings system:

BUY: stock expected to outperform the market by over 25% over a 12 month period;

OUTPERFORM: stock expected to outperform the market by between 10% and 25% over a 12 month period;

NEUTRAL: stock performance expected at between +10% and – 10% compared to the market over a 12 month period;

NDEDTRENGORM: stock expected to underperform the market by between –10% and -25% over a 12 month period;

SELL: stock expected to underperform the market by over 25% over a 12 month period.

Prices: The prices reported in the research refer to the price at the close of the previous day of trading

<u>CURRENT INVESTMENT RESEARCH RATING DISTRIBUTIONS</u>
Intermonte SIM is authorised by CONSOB to provide investment services and is listed at n° 246 in the register of brokerage firms.
As at 30 June 2022 Intermonte's Research Department covered 120 companies. Intermonte's distribution of stock ratings is as follows:

BUY:	21.95 %
OUTPERFORM:	48.78 %
NEUTRAL:	27.64 %
UNDERPERFORM	01.63 %
SELL:	00.00 %

The distribution of stock ratings for companies which have received corporate finance services from Intermonte in the last 12 months (53 in total) is as follows:

BUY:	25.00 %
OUTPERFORM:	57.69 %
NEUTRAL:	17.31 %
UNDERPERFORM	00.00 %
SELL:	00.00 %

## CONFLICT OF INTEREST

In order to disclose its possible conflicts of interest Intermonte SIM states that:

Intermonte SIM SpA is acting as ECM Advisor in GPI's capital increase with an agreement with the company for the publication of an equity research regarding the company and the transaction. Intermonte will receive fees from the company for its activity as ECM Advisor.

Within the last year, Intermonte SIM managed or co-managed/is managing or is co-managed/is managing or OVS, Sedoc (on Cyberoo shares), SPSI (on Guala Closures shares), Tesmec, Tinexta and WIIT.

Intermente SIM provides investment banking services to Esprinet in connection with the non binding offer on Cellularline announced on the 7th of May 2022
Intermente SIM is Specialist and/or Corporate Broker and/or Sponsor and/or Broker in charge of the share buy back activity of the following Companies: Abitare In, Aedes, Alkemy, Anima, Aquafil, Avio, Banca Ifis, Banca Sistema, Cattolica, Cellularline, Civilariana Systems, Cyberoo, Cydgate, DeA Capital, ElEn, Eles, Elica, Emak, Esprinet, Expert Al, Falck Renewables, First Fondo Appla, Fine Foods, Gefran, Go Internet, Gpi, Greenthesis (formerly Ambienthesis), Gruppo Fos, GVS, IEG, Iervolino Entertainment, Indelb, Luve, Matica Fintec, Notorious Pictures, Nova Re SIIQ, Omer, Pharmanutra, Reevo Spa, Relatech, Reply, Retelit, Sababa Security, Saes Getters, Salcef, Sciuker Frames, Seco, Servizi Italia, Sesa, Serl Industrial, Somec, Tamburi, Tinexta, Tesmec, The Italian Sea Group, Txt and WIIT.

Intertance In Etalian Sea Group, Ixt and WIII.

Intermonte SIM has a contractual commitment to act as liquidity provider on behalf of third parties for the following company: Banca Sistema.

Intermonte SIM performes as a market maker for the following companies: A2A, Anima, Atlantia, Autogrill, Azimut Holding, BAMI, Banca Generali, Banca Mediolanum, Brembo, Buzzi, CNHI, Enel, ENI, Exor, Fineco, FCA, FTMIB, Generali, Italgas, Iren, Intess Sanpaolo, Leonardo, Mediobanca, Moncler, Medioset, Prysmian, Poste, Ferrari, Saipem, Snam, STM, Tenaris, Telecom Italia asv, Terna, UBI, Unicredit, Unipol, UnipolSai.

Intermonte SIM is a member of the CBOE Europe Equities Liquidity Provider Program for the following financial instruments: A2A, Atlantia, ATSM, Autogrill, Azimut Holding, Banca Generali, Banca Mediolanum, Banco BPM, Bca Monte dei Paschi di Siena, Bca Pop Emilia Romagna, Banca Pop Sondrio, Buzzi Unicem, Buzzi Unicem rsp, Campari, CIR- Compagnie Industriali Riunite, Credito Emiliano, Danieli & C., Danieli & C. Bisp NC, Diasorin, Enel, Eni, Generali, Hera, Intesa Sanpaolo, Iren, Italgas, Italmobiliare, Leonardo, Maire Tecnimont, Mediaset, Mediobanca, Pirelli & C., Poste Italiane, Prysmian, Recordati, S.I.A.S., Saipem, Salini Impregilo, Salvatore Ferragamo, Snam, Telecom Italia, Telecom Italia,

Reevo Spa, Relatech, Reti, Salcef Group, Sciuker Frames, Sebino, Sit Group, Sos Travel, Sourcesense, Spindox Digital Soul, Supplynecapital, Take Off, Tamburi, Tenax International, Tesmec, The Italian Sea Group, Tinexta, Tps, Trenddevice, Triboo, Ulisse Biomed, Unidata, Vantea Smart, Websolute, WIIT.

Intermonte SIM SpA holds net long or short positions in excess of 0.5% of the overall share capital in the following issuers:

Emittente	%	Long/Short

## © Copyright 2022 by Intermonte SIM - All rights reserved

It is a violation of national and international copyright laws to reproduce all or part of this publication by email, xerography, facsimile or any other means. The Copyright laws impose heavy liability for such infringement. The Reports of Intermonte SIM are provided to its clients only. If you are not a client of Intermonte SIM and receive emailed, faxed or copied versions of the reports from a source other than Intermonte SIM you are violating the Copyright Laws. This document is not for attribution in any publication, and you should not disseminate, distribute or copy this e-mail without the explicit written consent of Intermonte SIM.

INTERNONTE will take legal action against anybody transmitting/publishing its Research products without its express authorization.

INTERMONTE Sim strongly believes its research product on Italian equities is a value added product and deserves to be adequately paid.

Intermonte Sim sales representatives can be contacted to discuss terms and conditions to be supplied the INTERMONTE research product.

INTERMONTE SIM is MIFID compliant - for our Best Execution Policy please check our Website MIFID